These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10208642)

  • 1. The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation.
    Gill HJ; Tjia JF; Kitteringham NR; Pirmohamed M; Back DJ; Park BK
    Pharmacogenetics; 1999 Feb; 9(1):43-53. PubMed ID: 10208642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
    Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
    Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
    Yamazaki H; Inoue K; Shimada T
    Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allelic and functional variability of cytochrome P4502C9.
    Bhasker CR; Miners JO; Coulter S; Birkett DJ
    Pharmacogenetics; 1997 Feb; 7(1):51-8. PubMed ID: 9110362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
    Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
    Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
    Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA
    Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
    Tang C; Shou M; Rushmore TH; Mei Q; Sandhu P; Woolf EJ; Rose MJ; Gelmann A; Greenberg HE; De Lepeleire I; Van Hecken A; De Schepper PJ; Ebel DL; Schwartz JI; Rodrigues AD
    Pharmacogenetics; 2001 Apr; 11(3):223-35. PubMed ID: 11337938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
    Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
    Wester MR; Lasker JM; Johnson EF; Raucy JL
    Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis.
    Aithal GP; Day CP; Leathart JB; Daly AK
    Pharmacogenetics; 2000 Aug; 10(6):511-8. PubMed ID: 10975605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
    Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
    Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates.
    Takanashi K; Tainaka H; Kobayashi K; Yasumori T; Hosakawa M; Chiba K
    Pharmacogenetics; 2000 Mar; 10(2):95-104. PubMed ID: 10761997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach.
    Venkatakrishnan K; von Moltke LL; Greenblatt DJ
    J Pharm Sci; 1998 Jul; 87(7):845-53. PubMed ID: 9649353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
    Gentile DM; Verhoeven CH; Shimada T; Back DJ
    J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P-450 2C9-reconstituted system.
    Palamanda J; Feng WW; Lin CC; Nomeir AA
    Drug Metab Dispos; 2000 Jan; 28(1):38-43. PubMed ID: 10611138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
    Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
    J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes.
    Wang JS; Wen X; Backman JT; Neuvonen PJ
    J Pharmacol Exp Ther; 2002 Jul; 302(1):43-9. PubMed ID: 12065698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.